Login
$EQ
$1.23 +$0.08 (6.96%) After hours

$EQ SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 S-3
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027

12 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 SCHEDULE 13G/A
26 Oct 2026 8-K: Unregistered Sales of Equity Securities; Regulation FD Disclosure +1 more

Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027

05 Oct 2026 8-K: Other Events

On October 5, 2026, Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification...

13 Aug 2026 10-Q
13 Aug 2026 SCHEDULE 13G
13 Aug 2026 8-K: Results of Operations and Financial Condition

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter

12 Aug 2026 SCHEDULE 13G/A
05 Jun 2026 144
05 Jun 2026 Form 4: Zedelmayer Christine, Sr. Vice President and COO

Received 14,584 shares by exercise or conversion ($11.4K) · Sold 14,584 shares ($42.7K)

05 Jun 2026 Form 4: Connelly Stephen, President and CSO

Sold 200,000 shares ($633K) · Sold 30,975 shares ($91.1K)

04 Jun 2026 144
29 May 2026 Form 4: Tom Penny, Principal Accounting Officer

Received 65,000 shares by exercise or conversion ($51K) · Sold 65,000 shares ($192K)

29 May 2026 Form 4: Demski Martha J, Director

Granted 70,000 Director Stock Option (right to buy)

29 May 2026 Form 4: Pruzanski Mark, Director

Granted 70,000 Director Stock Option (right to buy)

29 May 2026 Form 4: Bradbury Daniel, Director

Granted 70,000 Director stock option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support